^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HH185

    i
    Associations
    News

    Trials

    Company:
    3DMed, CSPC Pharma, HaiHe Biopharma
    Drug class:
    FGFR1 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor, CSF-1R inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma (NCT05039892)
    Phase 2
    3D Medicines (Beijing) Co., Ltd.
    Not yet recruiting
    Last update posted :
    01/31/2024
    Initiation :
    12/01/2024
    Primary completion :
    12/01/2025
    Completion :
    06/01/2026
    FGFR
    |
    HH185